Cartilage regeneration using adipose-derived stem cells and the controlled-released hybrid microspheres

Han, Yisheng; Wei, Yiyong; Wang, Shuseng; Song, Yang

doi:10.1016/j.jbspin.2009.05.013

Cited by 42 publications

(40 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…31 Gelatin microspheres have been extensively studied for delivery of growth factors and stem cells. 26,[30][31][32][33] In this study, the amount of drug loaded and the resulting release kinetics were readily modulated by the concentration of simvastatin absorbed into the microspheres as well as the prewashing conditions. For the ''low-dose'' system, about 50% of loaded simvastatin was released during the first 2 days, whereas nearly 70% burst was observed for the ''high-dose'' system.…”

Section: Discussionmentioning

confidence: 91%

Development of an injectable two‐phase drug delivery system for sequential release of antiresorptive and osteogenic drugs

et al. 2011

View full text Add to dashboard Cite

Unlike controlled release systems that deliver a single drug, dual or multidrug delivery systems with distinct release profiles are more likely to promote timely and effective tissue regeneration as they provide both temporally and concentration-dependent release of different molecules to mimic natural biological events. In this study, an injectable and biodegradable delivery system was developed to sequentially release an antiresorptive drug (clodronate) followed by an osteogenic agent (simvastatin) to treat bone disease. The injectable delivery system comprised simvastatin-loaded gelatin microspheres suspended in a viscous solution of carboxymethylcellulose (CMC) containing clodronate. Several factors (CMC concentration, glutaraldehyde concentration, simvastatin loading, and gelatin microsphere processing conditions) were investigated for their effects on drug release. Clodronate release was not affected by CMC concentration, with complete delivery within 12 hr, and simvastatin release could be modulated by cross-linking of the gelatin microspheres, loading, and washing conditions. Burst release of simvastatin was reduced from 70% to 6% in conjunction with sustained release for up to 3 weeks. The combined system showed early release of the antiresorptive clodronate sequentially followed by sustained delivery of the osteogenic simvastatin. This robust and flexible two-phase delivery system may prove useful for applications in which multiple drug delivery is desired.

show abstract

Section: Discussionmentioning

confidence: 91%

Development of an injectable two‐phase drug delivery system for sequential release of antiresorptive and osteogenic drugs

et al. 2011

View full text Add to dashboard Cite

show abstract

“…of studiesReferencesCell SourceNo. of studies a ReferencesHuman73[48, 50, 52, 53, 168–236]Bone marrow62[48, 50–53, 164, 168, 170–173, 177–180, 182–185, 187, 188, 192, 195–197, 203, 206–210, 212, 216, 217, 219, 221, 223, 227, 230, 232–235, 237–255]Rabbit17[240–242, 246, 249, 252, 255–265]Adipose36[66, 169, 175, 176, 181, 186, 189, 193, 194, 199, 201, 202, 211, 214, 216, 218–220, 224, 228, 229, 231, 235, 242, 256, 257, 260–269]Bovine5[51, 164, 243, 245, 270]Synovium9[174, 191, 200…”

Section: Resultsmentioning

confidence: 99%

“…of studies (%)ReferencesGrowth factorNo. of studies (%)ReferencesTGF-β148 (44%)[50, 169–175, 189, 190, 192, 193, 195, 199, 202, 208, 210, 211, 213, 214, 216, 217, 220, 222–224, 228, 230–232, 234, 235, 244, 246, 249, 252–256, 258, 260–263, 266, 267, 270]SOX-51 (1%)[204]TGF-β332 (29%)[51, 162, 164, 168, 177, 181–184, 197, 200, 205–207, 218, 223–225, 227, 237, 239, 240, 245, 247, 248, 250, 251, 257, 259, 267, 268, 270]SOX-61 (1%)[204]BMP-213 (12%)[188, 202, 213, 219, 225–227, 229, 264, 265, 267, 270, 271]WNT3A1 (1%)…”

Section: Resultsmentioning

confidence: 99%

The use of mesenchymal stem cells for cartilage repair and regeneration: a systematic review

et al. 2017

View full text Add to dashboard Cite

BackgroundThe management of articular cartilage defects presents many clinical challenges due to its avascular, aneural and alymphatic nature. Bone marrow stimulation techniques, such as microfracture, are the most frequently used method in clinical practice however the resulting mixed fibrocartilage tissue which is inferior to native hyaline cartilage. Other methods have shown promise but are far from perfect. There is an unmet need and growing interest in regenerative medicine and tissue engineering to improve the outcome for patients requiring cartilage repair. Many published reviews on cartilage repair only list human clinical trials, underestimating the wealth of basic sciences and animal studies that are precursors to future research. We therefore set out to perform a systematic review of the literature to assess the translation of stem cell therapy to explore what research had been carried out at each of the stages of translation from bench-top (in vitro), animal (pre-clinical) and human studies (clinical) and assemble an evidence-based cascade for the responsible introduction of stem cell therapy for cartilage defects.Main body of abstractThis review was conducted in accordance to PRISMA guidelines using CINHAL, MEDLINE, EMBASE, Scopus and Web of Knowledge databases from 1st January 1900 to 30th June 2015. In total, there were 2880 studies identified of which 252 studies were included for analysis (100 articles for in vitro studies, 111 studies for animal studies; and 31 studies for human studies). There was a huge variance in cell source in pre-clinical studies both of terms of animal used, location of harvest (fat, marrow, blood or synovium) and allogeneicity. The use of scaffolds, growth factors, number of cell passages and number of cells used was hugely heterogeneous.Short conclusionsThis review offers a comprehensive assessment of the evidence behind the translation of basic science to the clinical practice of cartilage repair. It has revealed a lack of connectivity between the in vitro, pre-clinical and human data and a patchwork quilt of synergistic evidence. Drivers for progress in this space are largely driven by patient demand, surgeon inquisition and a regulatory framework that is learning at the same pace as new developments take place.

show abstract

“…TGF-b1 improves chondrogenic differentiation in chondroblasts (Fukumura et al, 1998;Hayes et al, 2001;Valcourt et al, 2003), and in mesenchymal cells (Goomer et al, 2000;Miura et al, 2002;Williams et al, 2003). Thus, controlled release of TGFb1 might be of great interest in tissue engineering for cartilage regeneration (Han et al, 2010;Reyes et al, 2014;Yin et al, 2014). Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable and biocompatible copolymer authorized by the Food and Drug Administration (FDA) for drug delivery.…”

Section: Introductionmentioning

confidence: 99%

Sustained release of TGF-β1 from biodegradable microparticles prepared by a new green process in CO2 medium

Swed

Cordonnier

Dénarnaud

et al. 2015

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Cartilage regeneration using adipose-derived stem cells and the controlled-released hybrid microspheres

Cited by 42 publications

References 18 publications

Development of an injectable two‐phase drug delivery system for sequential release of antiresorptive and osteogenic drugs

Development of an injectable two‐phase drug delivery system for sequential release of antiresorptive and osteogenic drugs

The use of mesenchymal stem cells for cartilage repair and regeneration: a systematic review

Sustained release of TGF-β1 from biodegradable microparticles prepared by a new green process in CO2 medium

Contact Info

Product

Resources

About